Shibuya-ku, Tokyo, Japan, Japan, Jul 05, 2021, 08:05 /Comserve / -- Additionally, many large or small scale companies are actively engaged in developing novel transdermal products which will drive the market growth to great extent.

The transdermal drug delivery devices market is estimated to represent a global market of USD 32.56 billion by 2016 with growth rate of 8.9%. Skin comprises of three distinct however internally dependent tissues. The layer has been categorized into vascular, stratified, and cellular epidermis. Over the past few decades, controlled drug delivery has become widely important across the pharma industry. This is the reason; transdermal drug delivery devices market is seen upward trend over the past few years. Due to technological advancements, which improve the drug absorption ability through the skin pores without rupturing the skin tissues, transdermal drug delivery has become widely accepted route of drug administration among the companies. It is being justified by the fact that in last few years, approximately 35 transdermal products are approved by the U.S. FDA. Transdermal drug delivery system is defined as the administration of the drugs through skin for the systemic circulation at a predetermined rate of time. The industry is growing constantly and currently represent around 12% of the global drug delivery system market. Benefits of this drug delivery systems are considered to be the primary driving factor for the market growth. For example, transdermal drug delivery offers effective use of therapeutics with short biological half-life, allow drug administration with narrow therapeutics window, and avoid drug degradation in acidic medium.

Request to Fill The Form To get Sample Copy of This Report: www.sdki.jp/sample-request-53397

Additionally, many large or small scale companies are actively engaged in developing novel transdermal products which will drive the market growth to great extent. For example, in December 2015, 4P Therapeutics LLC demonstrated the preclinical, proof of mechanism for the Transdermal Follicle Stimulating Hormone delivery patch in infertility treatment. This demonstration was done to exhibit the preclinical efficacy of this system in reducing patient pain and thus improving patient compliance. Such initiatives will increase the product penetration hence drives the market growth. However, large molecular size therapeutics are not recommended to administer through this delivery system owing to its potential side effects, leading to hamper the market growth to some extent.

The market is primarily categorized into two categories such as technology and application. In terms of technology, the market is analyzed as Thermal, Mechanical arrays, Ultrasound, Microporation, Electroporation, Iontophoresis, and Others. Iontophoresis segment is accounted for the largest share of the global market, captured 17.23% share of the market in 2016. High efficiency coupled with ability of this technique to administer wide range of particles drive segment growth. These drug molecules primarily include insulin, hormones, proteins, and peptides. In its ability to deliver anionic, cationic, and hydrophilic drugs, is also responsible for the significant revenue of this segment.

The MARKET, BY APPLICATION is divided into CNS, Pain Management, Hormone and Others. Among different application area, pain management is considered to be the largest revenue generating segment, accounted for more than 5.1 billion in 2016. Availability of wide range of therapeutics that can be used for transdermal delivery for pain treatment helped this segment to augment the market growth.

Companies such as Novartis, Johnson & Johnson, Mylan, Boehringer Ingelheim, Biogel Technologies Inc., and Transdermal Technologies Inc. are operating in this market. Strategic merger and acquisitions and rising research and development acitivities to introduce new delivery system is considered to be the primary strategies of companies to expand their market share.

The market size and forecast for each segment has been provided for the period 2014 to 2025, considering 2015 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2016 to 2025 for every reported segment.

The years considered for the study are:

Historical Year – 2014 & 2015

Base Year – 2015

Estimated Year – 2016

Projected Year – 2025

TARGET AUDIENCE

Traders, Distributors, And Suppliers

Manufacturers

Hospitals

Government and Regional Agencies and Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT


The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY TECHNOLOGY

Thermal

Mechanical arrays

Ultrasound

Microporation

Electroporation

Iontophoresis

Others

MARKET, BY APPLICATION

CNS

Pain Management

Hormone

Others

MARKET, BY REGION

North America

Europe

Asia Pacific

Rest of the World

MARKET, BY COUNTRY

Further Breakdown of The North America Market

U.S.

Canada

Further Breakdown of The Europe Market

Germany

France

Rest of Europe

Further Breakdown of The APAC Market

India

China

Rest of APAC

Further Breakdown of The Rest of the World Market

Middle East and Africa

Latin America

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

For more information, please contact:

Hina Miyazu

Shibuya Data Count
Email: [email protected]
Tel: + 81 3 45720790

Related Links
www.sdki.jp/



Source link